## **Core Concept**
The question tests knowledge of anticoagulant medications, specifically oral direct thrombin inhibitors (DTIs) used for stroke prevention. Direct thrombin inhibitors are a class of anticoagulants that directly inhibit thrombin, a key enzyme in the coagulation cascade. They are used to prevent and treat thrombotic disorders.

## **Why the Correct Answer is Right**
Dabigatran (**Option D**) is a recent oral direct thrombin inhibitor that has been approved for the prevention of stroke in patients with non-valvular atrial fibrillation. It works by directly inhibiting thrombin, thereby reducing the formation of blood clots. Dabigatran has been shown to be effective in reducing the risk of stroke and systemic embolism in these patients.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is blank and does not provide a valid choice for consideration.
- **Option B:** This option is also blank and does not offer a viable alternative.
- **Option C:** Similarly, this option is blank and lacks relevance to the question.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that dabigatran is a direct oral anticoagulant (DOAC) that does not require regular monitoring of coagulation parameters like warfarin does. However, it is crucial to assess renal function before initiating dabigatran, as it is primarily excreted by the kidneys.

## **Correct Answer:** D. Dabigatran.